The treatment of plasma cell myeloma.
D000818:Animals; D002330:Carmustine / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D008807:Mice, Inbred BALB C; D009101:Multiple Myeloma / Q000188:drug therapy*; D009194:Myeloma Proteins / Q000097:blood; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D012075:Remission, Spontaneous
D009194:Myeloma Proteins; D003561:Cytarabine; D011344:Procarbazine; D004317:Doxorubicin; D008558:Melphalan; D005472:Fluorouracil; D002330:Carmustine; D011241:Prednisone; D008727:Methotrexate